Mylan NV, of Canonsburg, Pa., said its abbreviated new drug application for fluticasone propionate 100 mcg, 250 mcg, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted for filing by the FDA, which provided a GDUFA goal date of March 28, 2017. The product is the generic version of London-based Glaxosmithkline plc's Advair Diskus for the treatment of asthma and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease.